Rosetta cancer test receives coverage at major health insurer

Rosetta Genomics' (ROSG) shares are +9% after saying that its Cancer Origin Test is being covered by Highmark Health Services, the fourth largest U.S. Blue Cross and Blue Shield-Affiliated company.

Highmark has 5.3M members in Pennsylvania, Delaware and West Virginia. The test is now available to one in five people in the U.S.

The product tests for the origin of tumors in Cancer of Unknown or Uncertain Primary (CUP). (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs